Achillion Pharmaceuticals, Inc. (ACHN) financial statements (2020 and earlier)

Company profile

Business Address 300 GEORGE STREET
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15450300364459153122
Cash and cash equivalents44504377827433
Short-term investments110 2572873787988
Restricted cash and investments0      
Receivables 121210
Prepaid expense 000000
Income taxes receivable0
Other undisclosed current assets4224217112
Total current assets:158275304383463155125
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment1233221
Long-term investments and receivables75 3128  36
Long-term investments75 3128  36
Restricted cash and investments 000000
Deferred costs     00
Other noncurrent assets00000  
Total noncurrent assets:79234312238
TOTAL ASSETS:236278338414465157162
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17121314141410
Accounts payable3257465
Accrued liabilities149771065
Employee-related liabilities     11
Debt1000000
Other undisclosed current liabilities     (1)(1)
Total current liabilities:1812131415139
Noncurrent Liabilities
Long-term debt and lease obligation2 00000
Long-term debt, excluding current maturities  00000
Operating lease, liability2
Liabilities, other than long-term debt 000   
Deferred revenue and credits00   
Deferred rent credit 0
Total noncurrent liabilities:2000000
Total liabilities:1912131415139
Stockholders' equity
Stockholders' equity attributable to parent217266325399450143153
Common stock0000000
Common stock, share subscribed but unissued, subscriptions receivable     (6) 
Additional paid in capital948939927917905600535
Accumulated other comprehensive income (loss)0(0)(0)0(0)(0)0
Accumulated deficit(731)(673)(603)(517)(456)(451)(382)
Total stockholders' equity:217266325399450143153
TOTAL LIABILITIES AND EQUITY:236278338414465157162

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:   1566  
Operating expenses(81)(76)(90)(80)(81)(69)(59)
Operating loss:(81)(76)(90)(65)(15)(69)(59)
Nonoperating income
(Investment Income, Nonoperating)
6643101
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(75)(70)(85)(62)(14)(69)(59)
Income tax expense     (30) 
Net loss:(75)(70)(85)(62)(14)(99)(59)
Other undisclosed net income attributable to parent    930 
Net loss available to common stockholders, diluted:(75)(70)(85)(62)(5)(69)(59)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(75)(70)(85)(62)(14)(99)(59)
Other comprehensive income (loss)00(1)0(0)(0)(0)
Other undisclosed comprehensive income0      
Comprehensive loss:(74)(70)(86)(62)(14)(99)(59)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)   930 
Comprehensive loss, net of tax, attributable to parent:(74)(70)(86)(62)(5)(69)(59)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: